---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-018223"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:52:30.417586+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Natera Q4 revenue $476M (+53% YoY); guides 2025 revenue $1.87-1.95B

## Summary
- Q4 total revenue $476.1M (+53% YoY); product revenue $472.9M (+53.9%).
- Q4 gross margin 62.9% vs 51.4% a year ago; FY2024 GM 60.3%.
- Q4 net loss $53.8M ($0.41/share) vs $78.0M ($0.65) in Q4 2023; op loss $64.7M.
- Oncology tests in Q4 150,800 (+54.7% YoY); total tests 792,800 (+26.5%).
- FY2025 guidance: rev $1.87-1.95B; GM ~60-64%; positive net cash inflow.

## SEC filing metadata
- accession: 0001104659-25-018223
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465925018223/0001104659-25-018223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465925018223/tm257259d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-018223
- JSON: https://secwatch.observer/filing/0001104659-25-018223.json
- Plain text: https://secwatch.observer/filing/0001104659-25-018223.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.